Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 109 to 113 of 113 entries
Sorted by: Best Match Show Resources per page
[Diabetes mellitus and congestive heart failure: physiopathology and treatment].

Revue medicale suisse

De Flines J, Scheen AJ.
PMID: 16972538
Rev Med Suisse. 2006 Aug 23;2(76):1893-6, 1898-900.

Diabetes mellitus increases by 2.5 to 5 the relative risk of congestive heart failure. Besides the classical risk factors of congestive heart failure such as obesity, arterial hypertension and coronary artery disease that are frequently associated to type 2...

Cite
De Flines J, Scheen AJ. Diabète sucré et décompensation cardiaque: spécificités ethiopathogéniques et thérapeutiques. [Diabetes mellitus and congestive heart failure: physiopathology and treatment]. Rev Med Suisse. 2006;2(76):1893-6, 1898-900
De Flines, J., & Scheen, A. J. (2006). Diabète sucré et décompensation cardiaque: spécificités ethiopathogéniques et thérapeutiques. [Diabetes mellitus and congestive heart failure: physiopathology and treatment]. Revue medicale suisse, 2(76), 1893-6, 1898-900.
De Flines, J, and Scheen, A J. "Diabète sucré et décompensation cardiaque: spécificités ethiopathogéniques et thérapeutiques." [Diabetes mellitus and congestive heart failure: physiopathology and treatment]. Revue medicale suisse vol. 2,76 (2006): 1893-6, 1898-900.
De Flines J, Scheen AJ. Diabète sucré et décompensation cardiaque: spécificités ethiopathogéniques et thérapeutiques. [Diabetes mellitus and congestive heart failure: physiopathology and treatment]. Rev Med Suisse. 2006 Aug 23;2(76):1893-6, 1898-900. French. PMID: 16972538.
Copy Download .nbib Format: NLM
Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus.

Endocrinology and metabolism clinics of North America

Jorsal A, Wiggers H, McMurray JJV.
PMID: 29407047
Endocrinol Metab Clin North Am. 2018 Mar;47(1):117-135. doi: 10.1016/j.ecl.2017.10.007. Epub 2017 Dec 08.

This article briefly discusses the epidemiology of heart failure and diabetes and summarizes the key findings from the recent cardiovascular outcome trials in patients with type 2 diabetes, with a focus on heart failure as an endpoint.

Cite
Jorsal A, Wiggers H, McMurray JJV. Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. Endocrinol Metab Clin North Am. 2017;47(1):117-135doi: 10.1016/j.ecl.2017.10.007.
Jorsal, A., Wiggers, H., & McMurray, J. J. V. (2018). Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. Endocrinology and metabolism clinics of North America, 47(1), 117-135. https://doi.org/10.1016/j.ecl.2017.10.007
Jorsal, Anders, et al. "Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus." Endocrinology and metabolism clinics of North America vol. 47,1 (2018): 117-135. doi: https://doi.org/10.1016/j.ecl.2017.10.007
Jorsal A, Wiggers H, McMurray JJV. Heart Failure: Epidemiology, Pathophysiology, and Management of Heart Failure in Diabetes Mellitus. Endocrinol Metab Clin North Am. 2018 Mar;47(1):117-135. doi: 10.1016/j.ecl.2017.10.007. Epub 2017 Dec 08. PMID: 29407047.
Copy Download .nbib Format: NLM
Food and Pharma: Linking 2 Silos of Heart Failure Research and Therapy.

Journal of the American College of Cardiology

Gottlieb SH.
PMID: 33958129
J Am Coll Cardiol. 2021 May 11;77(18):2320-2322. doi: 10.1016/j.jacc.2021.03.311.

No abstract available.

Cite
Gottlieb SH. Food and Pharma: Linking 2 Silos of Heart Failure Research and Therapy. J Am Coll Cardiol. 2021;77(18):2320-2322doi: 10.1016/j.jacc.2021.03.311.
Gottlieb, S. H. (2021). Food and Pharma: Linking 2 Silos of Heart Failure Research and Therapy. Journal of the American College of Cardiology, 77(18), 2320-2322. https://doi.org/10.1016/j.jacc.2021.03.311
Gottlieb, Sheldon H. "Food and Pharma: Linking 2 Silos of Heart Failure Research and Therapy." Journal of the American College of Cardiology vol. 77,18 (2021): 2320-2322. doi: https://doi.org/10.1016/j.jacc.2021.03.311
Gottlieb SH. Food and Pharma: Linking 2 Silos of Heart Failure Research and Therapy. J Am Coll Cardiol. 2021 May 11;77(18):2320-2322. doi: 10.1016/j.jacc.2021.03.311. PMID: 33958129.
Copy Download .nbib Format: NLM
Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials.

American heart journal

Moghaddam N, Malhi N, Toma M.
PMID: 34283990
Am Heart J. 2021 Nov;241:74-82. doi: 10.1016/j.ahj.2021.07.003. Epub 2021 Jul 18.

BACKGROUND: Soluble guanylate cyclase (sGC) stimulators are a novel class of medications with emerging role in heart failure (HF). The aim of this study is to evaluate the efficacy and safety of oral sGC stimulators in patients with HF...

Cite
Moghaddam N, Malhi N, Toma M. Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials. Am Heart J. 2021;241:74-82doi: 10.1016/j.ahj.2021.07.003.
Moghaddam, N., Malhi, N., & Toma, M. (2021). Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials. American heart journal, 24174-82. https://doi.org/10.1016/j.ahj.2021.07.003
Moghaddam, Nima, et al. "Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials." American heart journal vol. 241 (2021): 74-82. doi: https://doi.org/10.1016/j.ahj.2021.07.003
Moghaddam N, Malhi N, Toma M. Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials. Am Heart J. 2021 Nov;241:74-82. doi: 10.1016/j.ahj.2021.07.003. Epub 2021 Jul 18. PMID: 34283990.
Copy Download .nbib Format: NLM
SGLT-2 Inhibitors in Heart Failure: Volume or Value?.

Journal of the American College of Cardiology

Kosiborod MN, Vaduganathan M.
PMID: 33736820
J Am Coll Cardiol. 2021 Mar 23;77(11):1393-1396. doi: 10.1016/j.jacc.2021.02.005.

No abstract available.

Cite
Kosiborod MN, Vaduganathan M. SGLT-2 Inhibitors in Heart Failure: Volume or Value?. J Am Coll Cardiol. 2021;77(11):1393-1396doi: 10.1016/j.jacc.2021.02.005.
Kosiborod, M. N., & Vaduganathan, M. (2021). SGLT-2 Inhibitors in Heart Failure: Volume or Value?. Journal of the American College of Cardiology, 77(11), 1393-1396. https://doi.org/10.1016/j.jacc.2021.02.005
Kosiborod, Mikhail N, and Vaduganathan, Muthiah. "SGLT-2 Inhibitors in Heart Failure: Volume or Value?." Journal of the American College of Cardiology vol. 77,11 (2021): 1393-1396. doi: https://doi.org/10.1016/j.jacc.2021.02.005
Kosiborod MN, Vaduganathan M. SGLT-2 Inhibitors in Heart Failure: Volume or Value?. J Am Coll Cardiol. 2021 Mar 23;77(11):1393-1396. doi: 10.1016/j.jacc.2021.02.005. PMID: 33736820.
Copy Download .nbib Format: NLM
Showing 109 to 113 of 113 entries